Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented updated data for its Filspari in IgA nephropathy and focal segmental glomerulosclerosis, reiterating the drug’s “robust clinical profile,” the analyst tells investors. While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentiated mechanism and broader label.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $47 from $45 at Canaccord
- Travere Therapeutics price target lowered to $27 from $31 at BofA
- Travere Therapeutics price target raised to $31 from $29 at BofA
- Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities
- Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS